{"entity":{"id":"nct01137682","kind":"trial","name":"Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly","aka":["PAOLA"],"tldr":"A phase 3 trial of Pasireotide in Pituitary tumours, run by Novartis Pharmaceuticals, completed.","summary":"Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly is a phase 3 interventional study registered as NCT01137682 by Novartis Pharmaceuticals, with 198 participants recorded, started 2010-07-19 and reaching its primary completion in 2013-01-22. Interventions recorded: Pasireotide, octreotide LAR 30mg, lanreotide ATG 120mg. Conditions recorded: Acromegaly.\n\nLinked to the drug Pasireotide because the registry names it among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT01137682","url":"https://clinicaltrials.gov/study/NCT01137682"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pituitary-tumours"],"sections":[],"technologies":[],"targets":[],"drugs":["pasireotide"],"companies":["novartis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01137682","phase":"3","setting":"A Phase III, Multicenter, Randomized, Parallel-group Study to Assess the Efficacy and Safety of Double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg Versus Open-label Octreotide LAR or Lanreotide ATG in Patients With Inadequately Controlled Acromegaly","sponsor":"Novartis Pharmaceuticals","started":"2010-07-19","startedType":"actual","yearReported":2015,"enrolled":198,"enrolledBasis":"registry","outcomes":[{"endpoint":"Percentage of Participants With a Reduction of Mean GH Levels to < 2.5 µg/L and Normalization of Sex- and Age-adjusted IGF-1.","primary":true,"unit":"%","arms":[{"name":"Pasireotide LAR 40 mg","n":65,"value":15.4,"note":"95% CI 7.63 to 26.48; Figures from the ClinicalTrials.gov results section (first posted 2015-01-21), not from a publication"},{"name":"Pasireotide LAR 60 mg","n":65,"value":20,"note":"95% CI 11.10 to 31.77"},{"name":"Control Arm (Octreotide or Lanreotide)","n":68,"value":0,"note":"95% CI 0 to 5.28"}],"source":"https://clinicaltrials.gov/study/NCT01137682?tab=results"}]},"route":"/trials/nct01137682/","neighbours":{"cancer":[{"id":"pituitary-tumours","kind":"cancer","name":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","route":"/cancers/pituitary-tumours/"}],"drug":[{"id":"pasireotide","kind":"drug","name":"Pasireotide","route":"/drugs/pasireotide/"}],"company":[{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"}]}}